New Approaches to Optimize Asparaginase Therapy in the Management of Acute Lymphoblastic Leukemia

Join us live in Chicago or via simulcast for this 1.5-hour, live interactive CME-certified symposium where an expert panel will review the latest evidence to optimize the care of AYA and adult patients with acute lymphoblastic leukemia using asparaginase-based therapies, including discussion of patient cases and practical guidance on strategies to increase completion of asparaginase treatment. Throughout the symposium, learners will have the opportunity to directly text questions to the panel. Register now!

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.


  • Welcome and Introduction
  • Background: Applying Lessons and Experience in Pediatric Patients to the Treatment of AYA and Adult Patients With ALL – Daniel J. DeAngelo, MD, PhD
  • Practical Considerations for Administration of Asparaginase-Based Therapy to Patients with ALL – Kjeld Schmiegelow, MD
  • Strategies to Mitigate Adverse Events with Asparaginase Treatment in Patients With ALL – Emily Curran, MD
  • Final Panel Discussion and Audience Question and Answer Session


Date / Time
Event Details


Program Director
Daniel J. DeAngelo, MD, PhD

Professor of Medicine
Department of Medicine
Harvard Medical School
Chief of the Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‚ÄźFarber Cancer Institute
Boston, Massachusetts

Emily Curran, MD

Assistant Professor
Division of Hematology/Oncology
University of Cincinnati Cancer Institute
Cincinnati, Ohio

Kjeld Schmiegelow, MD, DMSci

Department of Pediatric Oncology
Righospitalet University Hospital
Copenhagen, Denmark

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in integrating the latest data and strategies into treatment plans for patients with acute lymphoblastic leukemia.

Target Audience
This program is intended for physicians and other healthcare professionals who care for adolescent/young adult and adult patients with acute lymphoblastic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Select optimal asparaginase-containing regimens for adolescent/young adult and adult patients with ALL based on clinical data and expert recommendations
  • Identify optimal methods of measuring and monitoring subclinical hypersensitivity or silent inactivation
  • Implement optimal approaches to achieve continued and active asparaginase treatment, including activity level testing and premedication
  • Integrate newly approved dosing schedules or recombinant asparaginase formulations when considering asparaginase re-exposure of asparaginase treatments in adolescent/young adult and adult patients with ALL
  • Discuss recent clinical evidence and current recommendations for optimizing the therapeutic regimens for AYA ALL patients with pediatric-inspired protocols


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.